On December 14, 2020, Intellectual Property Co-Chair Philip Braginsky and Barry Marenberg co-authored the article, "Quantum Computing and Artificial Intelligence in Drug Discovery," featured in Patentography. The article delves into the implications of utilizing quantum computing and artificial intelligence to discover new drugs. The authors explain that drug development is a long process that comes with high risks and high costs. Therefore, incorporating advanced technology has the potential to transform the pharmaceutical industry and the production of drugs.
The development of drugs by quantum computing and artificial intelligence poses new patent considerations by the U.S. Patent and Trademark Office (USPTO). The article highlights the example of an innovation created by an artificial intelligence system. The inventor of the AI credited the machine as the "inventor" on the patent application. This designation was ultimately rejected by the USPTO. However, Phil notes that as innovations change the landscape of drug discovery, patent laws will need to adapt to technological advancements.
|Braginsky, Philip Partner and Co-Chair of Biologics Practice and China Practice||Partner and Co-Chair of Biologics Practice and China Practice||212.216.8065|